text
Vision Revolutionize the Administration of Advanced
Medicine to Solid Organs

We unleash the power of novel therapeutics by delivering them directly to the targeted organ.

Company Profile Leading Health Tech Company

Specializing in direct to organ delivery solutions for advanced medicine.

Founded
Scientific foundation in 2019, spun-out by DiNAQOR in 2023, led by Dr. Johannes Holzmeister, internationally recognized cardiologist and entrepreneur.
Innovation
1st company to demonstrate a proof of concept for a drug delivery solution that enables isolated organ delivery of therapeutic agents.
Management
Highly experienced management team with extensive expertise in the development and delivery of advanced medicines.
Strong Partners
Employs distinct partner strategy, aiming to build a sustainable pipeline and extend its reach to more patients, ensuring broad access to advanced medical therapies.
Locations
Headquarters:
Schlieren/Zurich, Switzerland

US Office:
Laguna Hills, CA, USA
Contacts
Wagistrasse 25,
8952 Schlieren/Zurich
P: +41 55 417 40 50
text
Partner of choice Isolate the Organ for Targeted Therapeutics
Vertically Integrated Multidisciplinary Organization
Translational

Advancing combinatory products into the clinic

Disease Strategy Pharmacology

Experimental and programmatic design

Engineering

System design, prototype and modifications to target organs to fit therapeutic purpose

Interventional

Conducting use experiments and refinements to achieve TPP

DiNATEQ™ Offers Full Scale Opportunities to Develop and Partner its Delivery Solution

Build and scale delivery system that is ready for multi-organ and clinical use

Advanced Therapy Solutions Group 21910 (1)
1
Patient Need

Targeting disease areas with high unmet medical needs and attractive commercial opportunities, where direct to organ delivery system can unleash full potential of therapeutics

2
System

Development of solution per targeted organ for the DiNATEQ™ system partnering with drug development companies

3
Expertise

Highly talented, cross-functional team combining expertise across anatomy, therapeutics and medical device

4
Partnerships

Broad range of alliances and partnership from single-asset to therapeutic fields across multiple modalities

5
Investments

Combining the potential of licensing and development fees, milestones and royalties

6
Evidence

Effectiveness of the system is supported through ongoing R&D with payloads and by comprehensive clinical data

Investment Thesis Multiple Collaboration Opportunities
Advanced Therapy Solutions Group (4)
In DiNATEQ™
Equity partner for the further scientific and commercial development of the business and its own therapeutics
Advanced Therapy Solutions Group (5)
Asset
License for the use of the LRP system for a specific drug or treatment
Advanced Therapy Solutions Group (6)
Therapeutic Field
License for the use of the LRP system for an entire sector
Advanced Therapy Solutions Vector (16)
Manufacturing
License for the manufacture, support, and distribution of the LRP system
text
We Have Established a Dominant IP Position for Closed-Loop Therapeutic Delivery to Solid Organs
Advanced Therapy Solutions Group 21910 (2)
AAV delivery to target organs via closed-loop system including specific AAVs of interest
Closed-loop perfusion systems for therapeutic delivery
Perfusion catheter and catheter component designs
Multiple organs including heart, kidney, liver, pancreas, spleen, and others (20+)
Management
 headshots-279x343_johannes M.D. Johannes Holzmeister Chairman and CEO
 Mark Dehdashtian Mark Dehdashtian Executive Vice President Medical Device
 headshots3_rusconi Chris Rusconi, PhD Chief Development Officer
 headshots-279x343_Steve_Zelenkofske Steven Zelenkofske, DO, MS Chief Strategy Officer
 Max Emmert Max Emmert, Prof. Medical Advisor
text
Get in Touch